Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

• Status: RECRUITING
• Trial end date: 2027-06-23

Summary

Orelabrutinib combined with rituximab (OR) therapy were used to assess the efficacy and safety for newly diagnosed Marginal zone cell lymphoma

• Phase: NA

Details

• Lead Sponsor: The First Affiliated Hospital of Xiamen University
• Collaborators: Chinese PLA General Hospital; Fujian Cancer Hospital; Guangdong Provincial People's Hospital; Jiangxi Provincial Cancer Hospital; Nanfang Hospital, Southern Medical University; Shaanxi Provincial Cancer Hospital; The First Hospital of Jilin University; The Second Affiliated Hospital of Dalian Medical University; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• Treatments: orelabrutinib; Rituximab